Oncology JP Morgan 2023 - Raj Chopra On the sidelines of JP Morgan 2023, pharmaphorum editor-in-chief Jonah Comstock sat down with Raj Chopra, acting CEO of Aethon Therapeutics.
Oncology After a slow start for expensive CAR-T therapies, drug devel... There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel o
Oncology Economist Impact: World Cancer Series – pharmaphorum in atte... Taking a brief look back to pharmaphorum’s coverage of Day One of The Economist’s 8th Annual
News EU approves AZ's Imfinzi plus chemo for advanced biliary tra... AstraZeneca’s (AZ) Imfinzi (durvalumab) has been approved in the
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
